ESR1 and breast carcinoma: To confirm the combinatorial efficacy of tamoxifen and talazoparib was not limited to the tamoxifen-resistant cells examined, we performed clonogenic survival assays in independently derived tamoxifen-resistant, ERα+ breast cancer cell lines (LCC2, LCC9; ref [33]).